---
title: "Ningbo Menovo Pharmaceutical Co.,Ltd. (603538.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603538.SH.md"
symbol: "603538.SH"
name: "Ningbo Menovo Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T08:16:11.548Z"
locales:
  - [en](https://longbridge.com/en/quote/603538.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603538.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603538.SH.md)
---

# Ningbo Menovo Pharmaceutical Co.,Ltd. (603538.SH)

## Company Overview

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.menovopharm.com/cn](https://www.menovopharm.com/cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 94 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 12.82% |  |
| Net Profit YoY | 51.61% |  |
| P/B Ratio | 5.34 |  |
| Dividend Ratio | 0.09% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12351611832.95 |  |
| Revenue | 1567073015.32 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.88% | C |
| Profit Margin | 7.17% | B |
| Gross Margin | 27.12% | C |
| Revenue YoY | 12.82% | B |
| Net Profit YoY | 51.61% | B |
| Total Assets YoY | -1.02% | D |
| Net Assets YoY | 7.49% | B |
| Cash Flow Margin | 139.84% | B |
| OCF YoY | 12.82% | B |
| Turnover | 0.34 | D |
| Gearing Ratio | 45.76% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ningbo Menovo Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "12.82%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "51.61%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.34",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.09%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12351611832.95",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1567073015.32",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.88%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "7.17%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "27.12%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "12.82%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "51.61%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.02%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.49%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "139.84%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "12.82%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.34",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "45.76%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 109.92 | 144/215 | 78.59 | 50.84 | 45.73 |
| PB | 5.34 | 193/215 | 2.78 | 2.21 | 1.98 |
| PS (TTM) | 7.88 | 165/215 | 4.30 | 3.32 | 2.91 |
| Dividend Yield | 0.09% | 155/215 | 0.24% | 0.22% | 0.13% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603538.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603538.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603538.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603538.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**